Hong Kong Luxury Stock News

SEHK:3800
SEHK:3800Semiconductor

GCL Technology Holdings (SEHK:3800) Valuation Check After 2025 Earnings Show Lower Sales And Narrowed Net Loss

What GCL Technology Holdings' Latest Earnings Mean For Investors GCL Technology Holdings (SEHK:3800) released full year 2025 results, reporting sales of CN¥14,424.93 million compared with CN¥15,097.56 million a year earlier, and a narrowed net loss of CN¥2,867.89 million. See our latest analysis for GCL Technology Holdings. The latest results arrived after a period where the share price has been under pressure, with a 30 day share price return of an 11.32% decline and a 90 day share price...
SEHK:622
SEHK:622Consumer Finance

Assessing Oshidori International Holdings (SEHK:622) Valuation After Its Earnings Turnaround To Net Income

Earnings turnaround puts Oshidori International Holdings (SEHK:622) in focus Oshidori International Holdings (SEHK:622) has caught investor attention after reporting full year 2025 earnings, shifting from a net loss to net income of HK$179.05 million with positive basic and diluted earnings per share. See our latest analysis for Oshidori International Holdings. At a share price of HK$1.73, Oshidori International Holdings has seen a 130.67% year to date share price return, while its 1 year...
SEHK:1209
SEHK:1209Real Estate

Assessing China Resources Mixc Lifestyle Services (SEHK:1209) Valuation After Strong 2025 Revenue And Net Income Growth

China Resources Mixc Lifestyle Services (SEHK:1209) has drawn fresh attention after reporting full year 2025 results, with sales of CN¥18,021.62 million and net income of CN¥3,969.02 million from continuing operations. See our latest analysis for China Resources Mixc Lifestyle Services. The earnings release comes after a strong run, with a 7 day share price return of 5.54% and a year to date share price return of 8.78%. The 1 year total shareholder return of 40.12% points to momentum that has...
SEHK:2186
SEHK:2186Pharmaceuticals

Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision

Why Luye Pharma’s latest earnings matter for investors Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend. The company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588...
SEHK:1816
SEHK:1816Renewable Energy

CGN Power (SEHK:1816) Valuation Check After Lower Earnings And Reduced Final Dividend

CGN Power (SEHK:1816) just reported full year 2025 results showing lower revenue and net income, alongside a proposed smaller final dividend of RMB 0.086 per share. This is putting income expectations and valuation under closer scrutiny for investors. See our latest analysis for CGN Power. The earnings and dividend announcement comes after a period of strong gains for investors, with a 30 day share price return of 12.46% and a 1 year total shareholder return of 43.16%. However, the 7 day...
SEHK:576
SEHK:576Infrastructure

A Look At Zhejiang Expressway (SEHK:576) Valuation After 2025 Results And Dividend Increase

Zhejiang Expressway (SEHK:576) has released new figures for its 2025 full year earnings, together with a proposed dividend increase. This combination gives income focused investors new information to assess. See our latest analysis for Zhejiang Expressway. At a share price of HK$7.45, Zhejiang Expressway has seen a 1 month share price return of 7.97%, while its 1 year total shareholder return of 21.27% and 3 year total shareholder return of 53.43% point to momentum that has built over time...
SEHK:3692
SEHK:3692Pharmaceuticals

Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval

What the latest earnings and drug news mean for Hansoh Pharmaceutical Group The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year 2025 earnings and new regulatory progress for its autoimmune drug XINYUE in China. For the year ended 31 December 2025, Hansoh Pharmaceutical Group reported sales of CN¥15,028.32 million, compared with CN¥12,260.81 million a year earlier, and net income of CN¥5,555.46 million versus CN¥4,371.83...
SEHK:639
SEHK:639Metals and Mining

A Look At Shougang Fushan Resources Group’s Valuation After Weaker 2025 Earnings And Dividend Proposal

What the latest earnings and dividend move mean for Shougang Fushan Resources Group (SEHK:639) Shougang Fushan Resources Group (SEHK:639) has drawn attention after reporting full year 2025 results showing lower net income and earnings per share, alongside a proposed final dividend of HK$0.06 per share. This combination of reduced profitability and a smaller final payout raises straightforward questions for you as a shareholder, especially around income expectations, payout sustainability, and...
SEHK:916
SEHK:916Renewable Energy

Assessing China Longyuan Power Group’s Valuation After Weaker 2025 Results And Earnings Decline

China Longyuan Power Group (SEHK:916) has released its full year 2025 results, reporting sales of CN¥30,252.71 million and net income of CN¥4,526.22 million, both lower than the previous year. See our latest analysis for China Longyuan Power Group. The stock has been under pressure in the past month, with an 8.69% 30 day share price return and a 9.04% 7 day share price return, although the 1 year total shareholder return of 14.31% contrasts with weaker 3 and 5 year total shareholder...
SEHK:981
SEHK:981Semiconductor

Assessing Semiconductor Manufacturing International’s Valuation After Recent Share Price Weakness

Assessing Semiconductor Manufacturing International after recent share price weakness Semiconductor Manufacturing International (SEHK:981) has come under pressure recently, with the share price showing a 3.5% decline over the past day and a 16.7% drop over the past month. For investors, this invites a fresh look at how the current valuation aligns with the company’s scale and earnings profile. See our latest analysis for Semiconductor Manufacturing International. At the current share price of...
SEHK:2556
SEHK:2556Software

Assessing Marketingforce Management (SEHK:2556) Valuation After Its Return To Profit And Strong Annual Results

Marketingforce Management (SEHK:2556) just posted full year 2025 earnings that shifted from a CNY 876.67 million net loss a year earlier to a CNY 88.94 million net profit, alongside higher reported sales and positive earnings per share. See our latest analysis for Marketingforce Management. Despite the swing back to profit, the recent share price performance has been weak. The 7 day share price return is 10.88% and the year to date share price return is 14.68%, while the 1 year total...
SEHK:1211
SEHK:1211Auto

A Look At BYD (SEHK:1211) Valuation After Recent Share Price Momentum

How BYD’s Recent Performance Sets the Stage for Investor Questions With no single headline event in play, BYD (SEHK:1211) has still drawn attention after a recent share price move, including a roughly 9% gain over the past month and a modest rise over the past 3 months. See our latest analysis for BYD. At the current share price of HK$103.9, BYD’s recent 1 month share price return of 9.31% and 3 month share price return of 5.22% sit against a 1 year total shareholder return decline of 15.92%...
SEHK:3931
SEHK:3931Auto Components

Assessing CALB Group (SEHK:3931) Valuation After Strong 2025 Earnings And Share Price Momentum

CALB Group (SEHK:3931) has just released its full year 2025 results, reporting sales of CN¥44,400.07 million and net income of CN¥1,475.63 million. These figures may influence how you assess the stock. See our latest analysis for CALB Group. The earnings release appears to sit alongside strong recent momentum, with a 30 day share price return of 29.11% and a 1 year total shareholder return of 86.44%. Meanwhile, the 3 year total shareholder return of 71.16% suggests earlier gains were more...
SEHK:881
SEHK:881Specialty Retail

Zhongsheng Group Holdings (SEHK:881) Valuation After 2025 Loss Dividend Halt And Leadership Changes

Zhongsheng Group Holdings (SEHK:881) released its full year 2025 results, reporting sales of CNY 164,403.43 million and a net loss of CNY 1,673.29 million. The company also announced a decision to skip the final dividend. See our latest analysis for Zhongsheng Group Holdings. The weak 30 day share price return of 11.09% and 90 day share price return of 27.04% point to fading momentum, and the 1 year total shareholder return of 33.28% underlines how pressure has built over time despite the...
SEHK:1114
SEHK:1114Auto

Assessing Brilliance China Automotive (SEHK:1114) Valuation After Mixed 2025 Earnings Results

Why Brilliance China Automotive’s latest earnings matter for shareholders Brilliance China Automotive Holdings (SEHK:1114) has just released full year 2025 results, reporting CNY 1,181.92 million in sales and CNY 1,985.69 million in net income, with earnings per share lower than in the prior year. See our latest analysis for Brilliance China Automotive Holdings. Brilliance China Automotive’s share price has pulled back recently, with a 30 day share price return showing a decline of 23.65% and...
SEHK:2669
SEHK:2669Real Estate

A Look At China Overseas Property Holdings (SEHK:2669) Valuation After 2025 Results And Final Dividend Proposal

China Overseas Property Holdings (SEHK:2669) has just released its full year 2025 results along with a proposed ordinary final dividend of HK$0.10 per share, giving investors fresh information on both operations and cash returns. See our latest analysis for China Overseas Property Holdings. At a share price of HK$4.03, the stock has a 90 day share price return of a 12.01% decline and a 1 year total shareholder return of a 23.35% decline, pointing to fading momentum despite the latest earnings...